

Update on the Supply of HPV Vaccine & Proposed Actions

Towards Elimination of Cervical Cancer in the Americas
1-2 August 2019

Outline



Resolution & Photo Exhibit PAHO Directing Council: It is time to end cervical cancer, September 2018



Ministers of health commit to
reducing cervical cancer
cases and deaths by 30%
in the Americas by 2030

VACUNACIÓN CONTRA EL VPH PARA LAS NIÑAS DE 9 A 14 AÑOS

Carla, Daniela y Stephanie recibieron la vacuna contra el VPH en Sacatepéquez, Guatemala. Desde la introducción de la vacuna VPH en la Región, más de 24 millones de dosis han sido gestionadas por el Fondo Rotatorio de la OPS para apoyar a los ministerios de salud y asegurar el acceso universal a vacunas seguras, eficaces y de calidad.

VACCINATION AGAINST HPV FOR 9-14 YEAR OLD GIRLS

Carla, Daniela and Stephanie received the HPV vaccine in Sacatepéquez, Guatemala. Since the introduction of the HPV vaccine in the Region, more than 24 million doses have been procured by the PAHO Revolving Fund to support the ministries of health in ensuring universal access to safe, effective and quality vaccines.

HPV Vaccine: Overview of Global Demand and Supply

- Supply not sufficient to meet demand until 2024 (and then only with tight management and careful planning)
- Factors that could affect demand/supply balance
 - Increase in projected capacity does not materialize timely and in the expected size.
 - Increase in global demand.
 - Pipeline products do not reach market (or PQ) as forecasted.
 - Demand of 9 valent increases substantially.
 - Additional countries extend immunization to boys
 - Country introductions and coverage increases do not occur as planned

Vaccine type	Manufacturer	Pharmaceutical form	Presentation	PQ date	Available to PAHO Revolving Fund
Human Papillomavirus (Bivalent) Cervarix	GSK	Liquid: Ready to use	Vial 1 dose Vial 2 doses +	08-07-2009	Through 2019
Human Papillomavirus (Quadrivalent) Gardasil	Merck	Liquid: Ready to use	Vial 1 dose	20-05-2009	Finalizing negotiations for continued supply
Human Papillomavirus (Ninevalent) Gardasil 9	Merck	Liquid: Ready to use	Vial 1 dose	09-02-2018	Not Available

WHO Working Group: 5.1


Increasing Coverage of HPV Vaccination

What has the WHO WG done thus far?

1. MI4A HPV Global Market Study



FIG. 3: DEMAND-SUPPLY BALANCE OVER TIME¹³




2. Presented HPV Market Study to SAGE Working Group, June 2019

Demand, Supply and Procurement of HPV Vaccine PAHO Revolving Fund, 2017-2020

Background: 40 countries in region
administering HPV vaccine – mature regional

ANTICIPATING LIMITED HPV VACCINE MARKET CONDITIONS in 2020

- Ensure purchases of all available doses for 2019 (1.4M doses in orders placed or in process; 1.4M doses pending).
- Support country transition(s) from Bivalent to Quadrivalent vaccine as needed.
- Continue with negotiation of new terms for 2020-2021 with remaining supplier
 - Improve delivery times from 12 to 8, to 6 weeks following receipt of the order
 - This requires monthly updates of country demand requirements with supplier
 - Concern remains for volumes and price.




negotiations with
of the HPV
progressively to
beginning in

market, leaving only one source of supply for
HPV vaccine in the short term (at least until
2022).

Four (4) additional countries requesting HPV
through the RF representing additional need of
1M ds (2019) and projected 2.5M ds (2020).

- (I) LTAs for 2017 and 2018 correspond to quantities estimated in the original agreements with suppliers without considering constraints (supply, funding).
 (II) LTA for 2019 was adjusted to reflect the availability offered by the suppliers.
 (III) Purchases 2019 (includes purchases in process as of 30 July 2019)
 (IV) Demand for 2020 is to be covered with HPV Quadrivalent only, however, the supply for the full quantity is pending.

Collaborative Effort to Ensure Timely Supply



PAHO Technical Advisory Group (TAG) Meeting Recommendations, Cartagena, July 2019

- TAG expresses deep concern over the current challenges facing the supply of HPV vaccine and stresses the importance of meeting countries' needs in order to reduce the burden of cervical cancer. TAG calls on the global public health community to challenge HPV vaccine manufacturers to be operationally and ethically responsive to global vaccine supply needs and align with PAHO/WHO's call for action for elimination of cervical cancer.
- In view of the current supply challenge, all countries administering vaccines to girls and boys should prioritize vaccination of girls, achieving HPV coverage >80%. This will induce herd immunity and protect both girls and boys.
- TAG encourages countries to implement school-based HPV vaccination and communication plans to accelerate vaccine uptake and maximize vaccination impact.

Next Steps

- Working with FPL/IM and NIPs, implement TAG recommendations.
- Review national HPV inventories and demand reconfirmations for Q3 and Q4 2019 to ensure all available doses (1.4million) are procured.
- HPV vaccine supply and price concerns beginning in 2020 and for at least 2 years, given sole source.
 - Sustain close working relationships with NIPs to prevent risk of stock-outs.
- For 2020, finalize negotiations to ensure:
 - PAHO, as part of its technical cooperation, determines with Member States the supply allocations in environment of limited supply.
 - Successful implementation of workplan with supplier to improve delivery times to countries in alignment with RF benchmark of 6 weeks.



Gracias
Merci
Obrigado
Thank You!

www.paho.org/immunization